Top San Diego, CA Software Companies With Best Stability & Growth (662)

Product Line Growth: Mobile lines are expanding rapidly, with Spectrum Mobile adding 406,000 lines in Q2 2026 to reach 12.5 million and mobile service revenue rising year over year.

Market Expansion: Rural buildouts and network extension are progressing, with 127,000 subsidized rural passings activated in Q2 2026 and a multi‑year initiative targeting more than 1.7 million new locations and 100,000+ miles of fiber.

Healthy Cash Flow: Quarterly free cash flow of $969 million alongside $2.9 billion of capex in Q2 2026 indicates capacity to fund network evolution and footprint growth despite a tougher backdrop.

Market Expansion: CSC operates in 140+ jurisdictions and opened a larger Luxembourg office in June 2024 to build for continued growth, citing an expanding local client base and about 600 staff there. Headcount disclosures reiterate a global workforce of more than 8,000, reflecting a broader operational footprint.

Product Line Growth: The Intertrust acquisition and full migration to the CSC brand in April 2024 expanded capabilities across corporate, fund, and capital‑markets administration. The Eddystone Financial Services acquisition in June 2023 added loan agency services in Australia and New Zealand, broadening regional offerings.

Strong Market Position & Advantage: CSC highlights service to more than 90% of the Fortune 500 and the 100 Best Global Brands, indicating deep enterprise penetration. Company materials emphasize a large, integrated platform serving clients in 140+ jurisdictions.

Strong Revenue Growth: Group sales increased 10% in 2025 and 9% in the first half of 2026, with underlying EBIT up 11%, and full‑year 2026 sales and EBIT guidance raised. These trends indicate broad-based momentum that includes U.S. programs.

Resilient & Sustainable Growth: A record order backlog of about £83.6–£84.0bn provides multi‑year revenue visibility and underpins capacity additions at U.S. sites. Free cash flow also strengthened, reinforcing durability of the growth profile.

Market Expansion: Facility expansions and upgrades in Endicott (NY), Austin (TX), Hudson (NH), and a new Utah site, alongside the 2024 acquisition of Ball Aerospace (now Space & Mission Systems), enlarge the U.S. footprint and portfolio. Recent U.S. and international contract wins further extend reach across markets.

Strong Revenue Growth: Revenue is on a clear upward trajectory, with estimates rising from 2024 through 2025, leadership guiding to a substantially larger 2026, and a stated path toward $1B by 2028. This momentum is tied to increasing orders, expanding programs, and a growing mix of software and systems.

Investor Backing & Capital Strength: A multi‑billion‑dollar capital package closed in March 2026, including a $1.5B Series G at a $12.7B valuation plus additional preferred equity and a delayed‑draw facility. This financing depth provides runway to scale autonomy software, aircraft programs, and the Aechelon acquisition.

Market Expansion: Operations and sales expanded internationally with new contracts across allies including Romania, Japan, Greece, and Canada, while U.S. traction includes Air Force CCA autonomy selections and a Navy contract to further develop X‑BAT. Over time, these moves broaden geographic reach and platform adoption.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Strong Revenue Growth: Revenue is described as scaling from roughly $3M to about $80M over the last few years, with Inc. 5000 recognition citing a three‑year surge. Ongoing federal awards and ACV disclosures further point to continued top‑line expansion into 2025–2026.

Profitability: Profitability is reported as achieved and sustained over multiple recent years, indicating growth without heavy burn. Claims of closing ~$80M in ACV alongside profitability reinforce durable unit economics.

Market Expansion: A DIU prototype transitioned to a production vehicle with a ceiling near $99M and procurement trackers show FY2025–FY2026 awards, signaling broader adoption across DoD units. Active hiring, expanding deployments, and mentions of footprints abroad suggest widening reach.

Product Line Growth: Recent launches such as Ace Mode for driver’s ed (with plans to extend to real estate and insurance) and a new e‑bike/e‑scooter safety course, alongside ongoing Android app updates, indicate sustained product investment and a widening catalog. These moves point to active iteration across core and adjacent offerings in 2026.

Market Expansion: Company materials cite operations across 40+ states and an expanding B2B/B2B2C channel via Aceable Partners for K‑12 districts, brokerages, and driving schools. Directional claims like 100+ district partners and multi‑state approvals suggest broader distribution beyond direct‑to‑consumer.

Investor Backing & Capital Strength: Disclosures of $100M+ raised, including a $50M growth investment, signal the resources to fund continued expansion. The careers page’s “profitable, growing team” language and active recruiting further support capacity to scale.

Strong Hiring & Retention: Hiring momentum, explicit “rapid growth” language on the careers page, and ongoing requisitions across Woburn/Boston, Arlington, Dayton, Melbourne, and San Diego point to expanding teams and stable retention. LinkedIn and careers postings indicate an active build-out across engineering and related functions.

Innovation-Driven Growth: Recent U.S. Navy awards, continued DARPA work through at least early 2026, and progress on multi‑phase programs (e.g., AIR and other DARPA initiatives) indicate expansion fueled by advanced R&D in AI/ML, sensing, cyber/EW, and mission software. Follow‑on options and modifications suggest programs are maturing rather than winding down.

Market Expansion: A five‑site U.S. footprint and active recruiting across these locations reflect scaled operations beyond a single hub. Participation on large DoD IDIQ vehicles and industry engagement (e.g., a CVPR 2026 workshop sponsorship) point to a widening market presence.

Strong Revenue Growth: Total revenue increased to $255.9M in 2025 with software up and drug‑discovery more than doubling, while operating expenses declined year over year. Early 2026 also showed momentum, with first‑half revenue modestly higher and Q2 posting year‑over‑year growth.

Strategic Partnerships: New and expanded agreements—such as Bristol Myers Squibb deploying Bunsen and a July 2026 discovery collaboration with Simcere—broaden platform use and collaboration optionality. The Lilly/Ajax transaction also validated the model and supported a higher 2026 drug‑discovery outlook.

Product Line Growth: The introduction of Bunsen, an agentic AI co‑scientist, expands the software portfolio and is being deployed at scale within BMS. This product push complements growth in ACV and broader platform adoption.

Strong Revenue Growth: Company communications highlight multi‑year revenue acceleration around the 2025 rebrand, alongside rising ARR and payment volume into 2026. Repeated Inc. 5000 recognition underscores sustained top‑line expansion.

Investor Backing & Capital Strength: A significant 2024 investment by Genstar Capital alongside TA Associates is positioned to fuel the next phase of scale. The 2026 appointment of a growth‑oriented CEO signals capacity to deploy this capital toward expansion.

Product Line Growth: LawPay was expanded into a broader financial management suite with offerings such as Smart Spend and a Visa business card, while multiple brands were unified under one platform to enable cross‑sell. New AI capabilities and integrations further extend the portfolio’s surface area.

Strong Revenue Growth: Revenue is described as accelerating sharply, with filings showing substantial year-over-year gains through 2024 and the first nine months of 2025, and independent estimates pointing to a billion‑dollar run rate in 2025. These trends align with rising client activity and balances disclosed alongside product launches.

Investor Backing & Capital Strength: New equity financing in January 2026 co‑led by Baillie Gifford and SBI Holdings, reports of a multibillion‑dollar pre‑IPO valuation, and outstanding senior notes expand financial capacity for scaling. These signals suggest ample capital to support continued build‑out and pre‑IPO positioning.

Market Expansion: Licenses in Europe, an APAC entry via the Boom Securities deal, and a trading app for sophisticated individual investors broaden both geography and customer segments beyond institutional prime brokerage. Cross‑margin and digital‑asset initiatives further indicate expansion into adjacent markets.

Strong Revenue Growth: Subscription revenue reached $3.877B in Q2 2026, growing strongly year over year, with total revenue also advancing. The company raised its full-year 2026 subscription outlook to $15.76–$15.78B and guided continued double-digit growth into Q3.

Product Line Growth: “ServiceNow AI” surpassed $1B in ACV in Q2 2026, acting as a catalyst for deal activity and upsell. Newer AI capabilities layered onto core workflows are described as adding incremental momentum.

Resilient & Sustainable Growth: Current and total RPO climbed to $13.20B and $29.0B, respectively, indicating strong contracted demand ahead. The number of customers above $5M in ACV increased meaningfully, supporting durable multi‑year expansion.

Strong Revenue Growth: ARR surpassing $100M around Jan–Feb 2025 and indications that FY2025 outpaced that rate point to sustained acceleration at scale. Subsequent updates describe strong year-over-year revenue growth continuing into 2026.

Market Expansion: Customer counts reaching 8,000+ across 80+ countries and 190% year-over-year enterprise growth highlight broadening adoption and upmarket traction. Moves such as opening a San Francisco HQ and expanding internationally reinforce geographic and segment reach.

Strong Market Position & Advantage: Consistent “Leader” placements in G2 category reports through 2025–2026 and coverage in Gartner Market Guides indicate durable category standing. Signals such as AWS Security Competency and expanding enterprise presence further reinforce competitive advantage.

Resilient & Sustainable Growth: Sales have been rising with management raising 2026 guidance, and a book-to-bill above 1 supports continued expansion from a record backlog. Quarterly gains across multiple periods point to steady, durable top-line momentum rather than one-off spikes.

Strong Market Position & Advantage: Prime roles on the B-21 Raider and LGM-35A Sentinel, along with top-tier industry rankings, demonstrate durable competitive standing in high-priority defense domains. A large, multi-year backlog underpins this position with clear demand visibility.

Diversified Revenue Streams: Multiple operating segments (Aeronautics, Mission Systems, Defense Systems, Space Systems) are contributing to sales and new awards, with several major programs ramping. Backlog and awards are distributed across sectors and programs, reducing reliance on any single line of business.

Strong Market Position & Advantage: The company is described as a leader in key infusion-therapy niches (notably needle-free connectors and closed-system drug handling) and, after acquiring Smiths Medical, operates as a top-tier, full-line competitor with bundling advantages across pumps, software, and consumables. Its breadth and ability to standardize across sites of care support competitiveness in large GPO/IDN bids.

Profitability: Recent disclosures highlight continued profitability and cash generation with improving gross margin and higher adjusted EBITDA guidance for 2026. Management points to mix improvement, cost actions, and integration benefits supporting margin progress.

Innovation-Driven Growth: Multiple recent 510(k) clearances for next‑generation Plum pumps and LifeShield software, along with resolved regulatory items, underscore ongoing product refresh and support forward execution. Pipeline activity and platform updates are positioned to reinforce the core infusion systems franchise.